Advertisement
ResearchIn-Press PreviewAIDS/HIVImmunology
Open Access |
10.1172/JCI207260
1Johns Hopkins University School of Medicine, Baltimore, United States of America
2Johns Hopkins University, Krieger School of Arts and Sciences, Baltimore, United States of America
3Maple Leaf Medical Clinic, Toronto, Canada
4UCSF, San Francisco, United States of America
Find articles by Bachmann, N. in: PubMed | Google Scholar
1Johns Hopkins University School of Medicine, Baltimore, United States of America
2Johns Hopkins University, Krieger School of Arts and Sciences, Baltimore, United States of America
3Maple Leaf Medical Clinic, Toronto, Canada
4UCSF, San Francisco, United States of America
Find articles by Kim, B. in: PubMed | Google Scholar
1Johns Hopkins University School of Medicine, Baltimore, United States of America
2Johns Hopkins University, Krieger School of Arts and Sciences, Baltimore, United States of America
3Maple Leaf Medical Clinic, Toronto, Canada
4UCSF, San Francisco, United States of America
Find articles by
Simonetti, F.
in:
PubMed
|
Google Scholar
|
1Johns Hopkins University School of Medicine, Baltimore, United States of America
2Johns Hopkins University, Krieger School of Arts and Sciences, Baltimore, United States of America
3Maple Leaf Medical Clinic, Toronto, Canada
4UCSF, San Francisco, United States of America
Find articles by Kovacs, C. in: PubMed | Google Scholar
1Johns Hopkins University School of Medicine, Baltimore, United States of America
2Johns Hopkins University, Krieger School of Arts and Sciences, Baltimore, United States of America
3Maple Leaf Medical Clinic, Toronto, Canada
4UCSF, San Francisco, United States of America
Find articles by
Hoh, R.
in:
PubMed
|
Google Scholar
|
1Johns Hopkins University School of Medicine, Baltimore, United States of America
2Johns Hopkins University, Krieger School of Arts and Sciences, Baltimore, United States of America
3Maple Leaf Medical Clinic, Toronto, Canada
4UCSF, San Francisco, United States of America
Find articles by
Deeks, S.
in:
PubMed
|
Google Scholar
|
1Johns Hopkins University School of Medicine, Baltimore, United States of America
2Johns Hopkins University, Krieger School of Arts and Sciences, Baltimore, United States of America
3Maple Leaf Medical Clinic, Toronto, Canada
4UCSF, San Francisco, United States of America
Find articles by Siliciano, J. in: PubMed | Google Scholar
1Johns Hopkins University School of Medicine, Baltimore, United States of America
2Johns Hopkins University, Krieger School of Arts and Sciences, Baltimore, United States of America
3Maple Leaf Medical Clinic, Toronto, Canada
4UCSF, San Francisco, United States of America
Find articles by
Siliciano, R.
in:
PubMed
|
Google Scholar
|
Published October 29, 2026 - More info
To eliminate the persistent reservoir of cells harboring intact HIV-1 proviruses in people living with HIV-1 (PLWH), cure strategies like the Shock-and-Kill approach rely on effector functions of cytolytic T lymphocytes (CTL). CTL are involved in the initial control of HIV-1 viremia and target productively infected cells throughout the course of infection. However, selective killing of susceptible cells could generate a reservoir dominated by cells with dysregulated cell death pathways or other features conferring resistance to killing. Here, we use CTL-engaging single-chain diabodies to assess the rate of lysis of uninfected and HIV-1-infected primary CD4+ T cells under identical CTL pressure in the settings of both latent and active infection. Our findings indicate that with this mode of CTL triggering, infected and uninfected CD4+ T cells from PLWH on ART are generally lysed at identical rates, and that an apparent survival advantage for actively infected CD4+ T cells primarily reflects the reduced surface antigen availability through previously described Nef-dependent downregulation of MHC class I molecules. No survival advantage is observed when the CTL response is directed through diabodies to the stably expressed non-classical MHC class I molecule HLA-E, indicating equal susceptibility to cell death.